Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
465 studies found for:    "Uveal diseases"
Show Display Options
Rank Status Study
1 Unknown  Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
Conditions: Behcet Syndrome;   Uveal Disease
Intervention: Drug: Etanercept, Methotrexate, Prednisolone
2 Recruiting Immunogenetic Mechanisms in Behcet's Disease
Conditions: Behcet's Disease;   Uveitis
3 Completed Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
Conditions: Diabetic Proliferative Retinopathy;   Vascular Vein Oclussion;   Choroidal Neovascularization
Intervention: Drug: Intravitreal Bevacizumab
4 Completed Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: MART-1 antigen;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: recombinant interleukin-12;   Biological: sargramostim;   Biological: tyrosinase peptide;   Drug: alum adjuvant;   Procedure: adjuvant therapy
5 Completed Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
Conditions: Melanoma (Skin);   Intraocular Melanoma
Interventions: Biological: Xenogeneic Tyrosinase DNA Vaccine;   Device: TriGrid Delivery System for Intramuscular Electroporation
6 Unknown  Myfortic for the Treatment of Non-infectious Intermediate Uveitis
Condition: Non-infectious Intermediate Uveitis
Interventions: Drug: Myfortic;   Drug: Decortin
7 Completed Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease
Condition: Behcet's Syndrome
Interventions: Drug: Rituximab;   Drug: Cytotoxic Combination
8 Recruiting Intestinal Bacteria and Ocular Inflammatory Disease
Conditions: Uveitis;   Age-Related Macular Degeneration
9 Completed Safety and Efficacy of AIN457 in Noninfectious Uveitis
Condition: Active Uveitis That is Not From an Infection.
Interventions: Drug: AIN457 subcutaneous dose;   Drug: AIN457 low dose (i.v);   Drug: AIN457 high dose (i.v)
10 Completed PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
Conditions: Choroidal Neovascularization;   Diabetic Retinopathy;   Diabetic Macular Edema
Interventions: Drug: PF-04523655 (Stratum I);   Drug: PF-04523655 and ranibizumab;   Drug: ranibizumab;   Drug: PF-04523655 (Stratum II)
11 Recruiting BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma
Condition: Choroidal Nevi, Uveal Melanoma
12 Completed Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Conditions: Age-Related Macular Degeneration;   Choroidal Neovascularization
Intervention: Drug: Adalimumab
13 Withdrawn Ustekinumab for Active Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Ustekinumab
14 Recruiting Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Conditions: Metastatic;   Uveal Melanoma
Interventions: Drug: 75mg selumetinib;   Drug: placebo;   Drug: Dacarbazine
15 Completed Positive Angle Kappa
Condition: Aniridia
16 Recruiting Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis
17 Completed Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Drug: ranibizumab
18 Active, not recruiting Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
Conditions: Choroidal Neovascularization;   Presumed Ocular Histoplasmosis
Intervention: Drug: EYLEA (Aflibercept) intravitreal injection
19 Completed Adherence With Fixed Versus Unfixed Glaucoma Therapy
Conditions: Primary Open-angle Glaucoma;   Ocular Hypertension;   Exfoliation Glaucoma
20 Active, not recruiting Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
Conditions: Uveitis;   Intermediate Uveitis;   Posterior Uveitis;   Panuveitis;   Noninfectious Uveitis
Intervention: Drug: triamcinolone acetonide (Triesence®)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years